N/A
Completed N=44,780
The INSPIRE-ASP PNA Trial
Source: ClinicalTrials.gov NCT03697070 ↗Enrolled (actual)
44,780
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 38690; 27971 Extended-Spectrum Days-of-Therapy
Summary
The INSPIRE-ASP PNA trial is a cluster-randomized controlled trial of HCA hospitals comparing routine empiric antibiotic stewardship practices with real-time precision medicine computerized physician order entry smart prompts providing the probability that a non-critically ill adult admitted with PNA is infected with a resistant pathogen.
Note: that enrolled "subjects" represents 59 individual HCA hospitals that have been randomized.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day |
38690; 27971 | — |
| SECONDARY Vancomycin Days of Antibacterial Therapy Per Empiric Day |
13778; 10534 | — |
| SECONDARY Antipseudomonal Antibiotic Days Of Therapy (ES-DOT) Per Empiric Day |
22683; 15670 | — |
Eligibility Criteria
Facility Inclusion Criteria:
- HCA hospitals admitting adults with PNA
- Facility use of MEDITECH as their electronic health record system
Facility Exclusion Criteria:
-
Note: unit of randomization is the hospital, however the CPOE alert intervention will calculate risk estimates for adults age >=18 admitted to non-ICU wards and who are ordered to receive extended-spectrum antibiotics for PNA. Prisoners were excluded from prompts and analysis.
Data sourced from ClinicalTrials.gov (NCT03697070). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.